Clinical trials: Ocular Graft Versus Host Disease
Dry Eye, Ocular Graft vs Host Disease
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
The objective of this study is to establish whether patients with dry eye disease (DED) are able to tolerate receiving Brimonidine: 0.15% eye drops two times a day for twelve weeks (primary tolerability objective) and to…
- Conditions
- Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
- Trial name
- NCT02975557
- Testing
- Brimonidine 0.15%, Brimonidine 0.075%
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sandeep Jain, MD
Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.
- Conditions
- Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum, Sjogren Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT03839069
- Testing
- minor salivary gland transplantation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Ocular Graft-versus-host Disease
Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT
Chronic GVHD (cGVHD) is a predominant cause of mortality and disability not related to relapse; it occurs in 30 to 70% of patients.
- Trial name
- NCT06348602
- Testing
- Cyclosporine ophthalmic solution 0.1%, Tacrolimus ophthalmic ointment 0.03%
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye
IVIG-eye Drops Treatment for Dry Eye Disease
The main objective of this study is to establish whether patients with Dry Eye Disease are able to safely tolerate receiving Intravenous Immunoglobulin (IVIG) eye drops two times a day for eight weeks (primary 'safety and…
- Trial name
- NCT03992482
- Testing
- Intravenous Immune Globulin (IVIG)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sandeep Jain, MD
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Ocular Graft-versus-host Disease
Vigamox Treatment for Ocular Graft-Versus-Host Disease
In this study the investigators seek to prospectively measure the response of ocular graft-versus-host disease (GVHD) patients to treatment with topical Vigamox.
- Trial name
- NCT04204122
- Testing
- Vigamox
- Sponsor
- Washington University School of Medicine
Ocular Graft-versus-host Disease
Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease
The study evaluates the efficacy and safety of allogeneic platelet lysate eye drops in patients with severe ocular graft versus host disease refractory to conventional systemic and local treatments.
- Trial name
- NCT05311514
- Testing
- Allogeneic platelet lysate eye drops
- Where
- Russia
- Volunteers
- 38 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Dacryocystitis, Dacryocystitis; Chronic
Examination of Lacrimal Sac and Nasal Mucosa Preparations Taken in Dacryocystorhinostomy Surgery of Patients With Nasolacrimal Duct Obstruction and Comparison of Clinical Groups With Each Other
The goal of this observational study is to investigate etiology and pathogenesis of nasolacrimal duct obstruction and dacryocystitis in different adult clinic groups.
- Conditions
- Dacryocystitis, Dacryocystitis; Chronic, Dacryocystorhinostomy, Epiphora
- Trial name
- NCT06810089
- Where
- Turkey (Türkiye)
- Volunteers
- 78 people
- Sponsor
- Uludag University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Ocular Graft-versus-host Disease
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
- Trial name
- NCT03990051
- Testing
- Pro-ocular™ topical gel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Glia, LLC
Dry Eye, Sjogren's Syndrome
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Severe dry eye is a debilitating ocular disease resulting in loss of vision, reduced day-to-day function and significant discomfort.
- Conditions
- Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
- Trial name
- NCT01393132
- Testing
- Thymosin Beta 4 eye drops, Vehicle Control
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Michigan Cornea Consultants, PC
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Graft vs Host Disease
A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
Some eye diseases can be helped by eye drops made from a person's own blood. These eye drops are called autologous serum eye drops, or ASEDs. ASEDs have been studied in only a few people with graft vs.
- Trial name
- GVHD ASED (NCT01972438)
- Testing
- ASEDs, Saline
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Eye Institute (NEI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
This Phase II clinical trial was designed for patients with hematologic malignancies in need of donor peripheral blood stem cell transplant, and have no HLA matched donor.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT01116232
- Testing
- anti-thymocyte globulin, rituximab, sirolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Rare Diseases, Aniridia
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with…
- Conditions
- Rare Diseases, Aniridia, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency
- Trial name
- NCT06412718
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele
Graft Vs Host Disease
Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes
To evaluate the safety and efficacy of Dextenza intracanalicular insert in patients with ocular graft-versus-host disease (GVHD).
- Trial name
- NCT04728646
- Testing
- DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use, Regular dissolvable intracanalicular plug
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Leukemia (Both ALL and AML), MDS-EB-1
Ikervis for DED Due to GVHD Post Allo-HSCT
Dry eye disease (DED) is a common sequelae of graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- Ikervis (NCT04636918)
- Testing
- Cyclosporine Ophthalmic
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore Eye Research Institute
Dry Eye Disease, oGVHD
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
Evaluate and study the immunologic changes to the ocular surface in cancer patients.
- Trial name
- NCT04946721
- Testing
- The standard care exam and biological specimens' collection
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Graft Versus Host Disease in Eye
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease.
- Trial name
- NCT05294666
- Testing
- Cyclosporine, tacrolimus
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Peking University Third Hospital